Tscan therapeutics to present updated data from the ongoing alloha™ phase 1 heme trial during oral session at the 66th american society of hematology annual meeting and exposition

To date, event-free survival strongly favors the treatment arm (hr=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (hr=0.28; p=0.14)

TCRX Ratings Summary

TCRX Quant Ranking